Appareil pulmonaire
TAS6417-201
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations.
Paris
NICOLAS GIRARD